Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjunctive Atorvastatin in Moderate-to-severe Thyroid Eye Disease (SEMAR-TED: Structural, Biomarker Expression and Muscle Endpoints of Atorvastatin): Study Protocol for a Randomised, Open-label, Assessor-masked Controlled Trial

NCT07762105 is registered in ClinicalTrials.gov with Banu Aji Dibyasakti as lead sponsor.

NCT NCT07762105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07762105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjunctive Atorvastatin in Moderate-to-severe Thyroid Eye Disease (SEMAR-TED: Structural, Biomarker Expression and Muscle Endpoints of Atorvastatin): Study Protocol for a Randomised, Open-label, Assessor-masked Controlled Trial
Lead sponsor
Banu Aji Dibyasakti
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 30, 2026
Completion date
September 30, 2027
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graves ophthalmopathy, graves orbitopathy, thyroid eye disease